Online inquiry

IVTScrip™ mRNA-Anti-CD274, MSB-0010718C(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12298MR)

This product GTTS-WQ12298MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CD274 gene. The antibody can be applied in Renal Cell Carcinoma (RCC), Merkel cell carcinoma (MCC) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001267706.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 29126
UniProt ID Q9NZQ7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD274, MSB-0010718C(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ12298MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ767MR IVTScrip™ mRNA-Anti-LOXL2, AB0024(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AB0024
GTTS-WQ13915MR IVTScrip™ mRNA-Anti-INHBA, REGN2477(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA REGN2477
GTTS-WQ12505MR IVTScrip™ mRNA-Anti-MUC5AC, NOE-102(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA NOE-102
GTTS-WQ5274MR IVTScrip™ mRNA-Anti-IL4-α, CD124(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CD124
GTTS-WQ6600MR IVTScrip™ mRNA-Anti-DPEP3, DC-1728001(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA DC-1728001
GTTS-WQ2845MR IVTScrip™ mRNA-Anti-ICOS, AMG-570(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AMG-570
GTTS-WQ2229MR IVTScrip™ mRNA-Anti-VWF, aVWF81(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA aVWF81
GTTS-WQ10636MR IVTScrip™ mRNA-Anti-MAPT, LY-3303560(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA LY-3303560
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW